Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma

An elevated body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) has been associated with an increased risk of renal cell carcinoma (RCC). 1 Previously, higher BMI was shown to be a positive prognostic factor for patients with metastatic clear cell RCC (mRCC) who were treated during the vascular endothelial growth factor (VEGF)-targeted therapy era. 2 However, the treatment landscape has shifted to include immune checkpoint inhibitors (ICIs) for most patients.We investigated t h i s o b e s it y p a r a d ox i n p at i e nt s w it h m RC C w h o were treated with programmed cell death 1 protein/ programmed cell death 1 ligand 1 (PD-1/PD-L1)-based ICIs and explored potential genomic alterations according to BMI status.